Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal PathLabs announced Q4FY24 results: Revenue increased by 11.1% in Q4FY24 EBITDA increased by 25.1% with a margin of 26.5% PAT increased by 50.8% with a margin for of 15.7% Result PDF
Conference Call with Dr. Lal Pathlabs Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q3FY24 & 9MFY24 results: Q3FY24: Revenue: In Q3FY24, Dr Lal PathLabs reported a revenue of Rs 539 crore, marking a 10.1% increase from the Rs 489 crore recorded in Q3FY23. Operating Expenditure: The operating expenditure rose by 5.8% to Rs 398 crore in the current quarter from Rs 376 crore in the corresponding quarter of the previous fiscal year. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): The Company's EBITDA escalated significantly by 24.6%, amounting to Rs 141 crore as compared to Rs 113 crore in Q3FY23, resulting in an EBITDA margin of 26.1%. Profit After Tax (PAT): PAT witnessed a substantial increase of 53.3% to Rs 82 crore in Q3FY24 from Rs 54 crore in Q3FY23, achieving a PAT margin of 15.3%. Earnings per Share (EPS): EPS climbed up to Rs 9.8, reflecting a remarkable 53.2% gain over the Rs 6.4 reported in Q3FY23. 9MFY24: Revenue: the Company's cumulative revenue reached Rs 1681 crore, which is a 10.2% increment year-on-year. Operating Expenditure: operating expenditure increased by 5.6% to Rs 1217 crore. EBITDA: EBITDA grew by 24.1% to Rs 465 crore, from Rs 374 crore with an improved margin of 27.6%. Profit After Tax (PAT): The nine months ended December 31, 2023, saw PAT soar by 50.5% to Rs 277 crore. Earnings per Share (EPS): EPS stood at Rs 32.9, an increase of 49.5% from the previous year. Result PDF